Injection proves effective in preventing HIV in women

A new anti-retroviral therapy given once every two months proves significantly more effective in preventing HIV infection in women than the current daily PrEP pills. — AFP

The new anti-retroviral therapy cabotegravir could be a “game changer” in preventing HIV (human immunodeficiency virus) infection in women, said the Joint United Nations Programme on HIV and AIDS (Unaids) on Nov 9 (2020).

Injected every two months, cabotegravir is 89% more effective in preventing HIV infection than daily pills of pre-exposure prophylaxis (PrEP) in women, according to the organisation.